26 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P-glycoprotein. DAY301 has been designed to maximize therapeutic index and overcome limitations
8-K
EX-99.3
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P
8-K
EX-10.1
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic
8-K
EX-1.1
hx9frwizkc1 8qen
7 Jun 23
Day One Announces Pricing of Public Offering of Common Stock
5:00pm
8-K
EX-1.1
ef9ti 5bx4f5ox
16 Jun 22
Day One Announces Pricing of Upsized Public Offering of Common Stock
7:33am
S-3
EX-1.2
xon7gp
1 Jun 22
Shelf registration
4:06pm
10-K
0nbxqc x00p1pwb1a
7 Mar 22
Annual report
7:36am
10-Q
phzi uy4dhtnijwlhx3
10 Aug 21
Quarterly report
5:26pm
424B4
ag4virxqwq9qi3
27 May 21
Prospectus supplement with pricing info
4:18pm